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Background
Schizophrenia is a highly heritable disorder with undetermined
neurobiological causes. Understanding the impact on brain
anatomy of carrying genetic risk for the disorder will contribute
to uncovering its neurobiological underpinnings.
Aims
To examine the effect of rare copy number variants (CNVs)
associated with schizophrenia on brain cortical anatomy in a
sample of unaffected participants from the UK Biobank.
Method
We used regression analyses to compare cortical thickness and
surface area (total and across gyri) between 120 unaffected
carriers of rare CNVs associated with schizophrenia and 16 670
participants without any pathogenic CNV. A measure of cortical
thickness and surface area covariance across gyri was also
compared between groups.
Results
Carrier status was associated with reduced surface area
(β =−0.020 mm2, P < 0.001) and less robustly with increased
cortical thickness (β = 0.015 mm, P = 0.035), and with increased
covariance in thickness (carriers z = 0.31 v. non-carriers z = 0.22,
P < 0.0005). Associations were mainly present in frontal and
parietal areas and driven by a limited number of rare risk alleles
included in our analyses (mainly 15q11.2 deletion for surface
area and 16p13.11 duplication for thickness covariance).
Conclusions
Results for surface area conformed with previous clinical
findings, supporting surface area reductions as an indicator of
genetic liability for schizophrenia. Results for cortical thickness,
though, argued against its validity as a potential risk marker.
Increased structural thickness covariance across gyri also
appears related to risk for schizophrenia. The heterogeneity
found across the effects of rare risk alleles suggests potential
different neurobiological gateways into schizophrenia’s
phenotype.
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Schizophrenia is a highly heritable (h2∼ 80%),1 severe and chronic
psychiatric disorder for which we have greatly advanced our under-
standing of the genetic risk factors;2,3 however, this has not been fol-
lowed by a significant improvement in our understanding of its
neurobiological underpinnings. Our knowledge about how genetic
risk alleles for schizophrenia affect brain anatomy is still scarce.
Recent research looking into rare risk alleles, such as copy
number variants (CNVs), has provided some clues. However,
most of these studies have suffered from low statistical power
and/or have included participants with severe psychopathology,
adding the confounding effect of variables related to the presence
of mental illness (i.e. medication or increased alcohol intake)
known to have an impact on brain anatomy.4–6 Since genetically
driven brain changes would be present – albeit attenuated – in
healthy at-risk participants, we aimed to investigate the effects of
schizophrenia- associated (SCZ-associated) CNVs on cortical thick-
ness and surface area in a sample of unaffected participants, there-
fore avoiding the above confounders. Cortical thickness and surface
area have been shown to be under different genetic influences in
adults and to capture different neurobiological aspects of brain
development, which justifies evaluating them separately rather
than in a combined measure of volume.7 We were also interested
in looking at the effect of SCZ-associated CNVs on cortical thick-
ness and surface area structural covariances. Structural covariance
networks are heritable8 and reflect patterns of maturational trajec-
tories,9 therefore providing potential valuable information on the
neurobiological substrates of schizophrenia.
Considering previous research in clinical samples,10 and assum-
ing that genetically driven brain changes will also express, albeit in an
attenuated form, in unaffected SCZ-associated CNV carriers, we
hypothesised that this group will present with thinner cortex and
reduced surface area compared with unaffected non-carriers, these
differences being larger in frontal and temporal regions. We also
hypothesised that SCZ-associated CNV carriers will present with
altered structural covariance compared with non-carriers, although
owing to the scarcity and inconsistency of results regarding cortical
thickness and surface area covariation,11,12 we did not make any a
priori assumption about the direction of this effect. We also aimed
to examine whether any effects of SCZ-associated CNVs over cortical
anatomy were generalisable across individual CNVs or whether indi-
vidual CNVs had distinctive effects over cortical anatomy.
Method
Participants
This study used a subsample of participants from the UK Biobank
(www.ukbiobank.ac.uk) for which brain magnetic resonance
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imaging (MRI) T1 images were available at the time of running the
analyses (n = 20 664). All participants have consented to take part
in genetic and imaging studies. The UK Biobank was granted
ethical approval by the North West Multi-Centre Research
Ethics Committee. Data were released to us under project reference
17044.
Only participants reporting White British or Irish descent
and for whom genetic analysis confirmed European ancestry13
(n = 18 534) were included. Furthermore, we excluded participants
with personal history of severe neuropsychiatric disorders or
medical/neurological conditions that could affect cortical
anatomy, using self-reported diagnosis made by a doctor at any
assessment visit or from hospital records, as follows: self-reported
from category 20002, including codes for other substance abuse/
dependency (1410), opioid dependency (1409), alcohol dependency
(1408), mania/bipolar disorder/manic depression (1291), schizo-
phrenia (1289), dementia/alzheimers/cognitive impairment
(1263), Parkinson’s disease (1262), multiple sclerosis (1261),
motor neuron disease (1259), chronic/degenerative neurological
problem (1258); and hospital records from categories 41202 and
41204, including ICD-10 codes for Down syndrome (Q90), perva-
sive developmental disorders (F84), mental retardation categories
(F71, F72, F73, F78, F79, F81), manic disorder/bipolar affective
disorder (F30, F31), other psychosis (F21, F22, F23, F28, F29),
schizoaffective disorders (F25), disorders due to psychoactive sub-
stance use (F11–F19), disorders due alcohol use (F10), dementia
(F00, F01, F02, F03, F04, G30, R54), multiple sclerosis (G35–
G37), neurodegenerative disorders (G11, G13, G23, G31, G32),
Alzheimer’s disease (G30), Parkinson’s disease (G20–G22),
motor neuron disease (G122) and Huntington’s disease (G10).
After applying these criteria, the sample size was reduced to 18
214 participants.
Genotyping and CNV calling
Genotyping was performed using the Affymetrix UK BiLEVE
Axiom® array (807 411 probes) on an initial 50 000 participants,
and the Affymetrix UK Biobank Axiom® array (820 967 probes)
for the remaining participants. The two arrays are very similar
(with over 95% common content). Sample processing at UK
Biobank is described in their documentation (https://biobank.ctsu.
ox.ac.uk/crystal/docs/genotyping_sample_workflow.pdf).
CNV calling was conducted following the same procedure as
described in a previous study.14 Briefly, normalised signal inten-
sity, genotype calls and confidences were generated using ∼750
000 biallelic markers that were further processed with
PennCNV-Affy software running in UNIX.15 Individual samples
were excluded if they had >30 CNVs, a waviness factor >0.03 or
<−0.03 or call rate <96%. After this quality control, the final
sample was reduced to n = 17 234. Individual CNVs were excluded
if they were covered by <10 probes or had a density coverage of <1
probe per 20 000 base pairs.14
A list of the CNVs that so far have been significantly associated
with schizophrenia3,16–18 and the genomic coordinates of their crit-
ical regions can be found in supplementary Table 1, available at
https://doi.org/10.1192/bjp.2020.139, along with their breakpoints.
These were manually inspected to confirm that they met our
CNV calling criteria. Briefly, we required a CNV to cover more
than half of the critical interval and to include the key genes in
the region (if known) or, in the case of single-gene CNVs, the dele-
tions to intersect at least one exon and the duplications to cover the
whole gene. As a control comparison, we used individuals who
carried none of the 93 CNVs that have previously been associated
with neurodevelopmental disorders19,20 (non-carriers). The criteria
for defining pathogenic CNVs have been previously fully
described.14 Applying these criteria excluded from our analyses
444 participants who carried at least one of these pathogenic
CNVs that have not yet been robustly associated with increased
risk for schizophrenia, bringing the total sample to n = 16 790
(120 carrying SCZ-associated CNVs and 16 670 non-carriers).
Brain imaging data
Brain images were acquired using Siemens Skyra 3 T scanners in
UK Biobank’s imaging centres in Cheadle (n = 14 154) and
Newcastle (n = 2636) using identical acquisition protocols.21 T1-
weighted brain images were processed using FreeSurfer v.5.3 soft-
ware running in UNIX (https://surfer.nmr.mgh.harvard.edu) to
automatically obtain estimates of mean cortical thickness (mm)
and surface area (mm2) for the whole brain and for each gyrus,
based on the Desikan–Killiany (D–K) atlas22 parcellation included
in FreeSurfer. To avoid error values due to deficient segmentation
of tissue types or parcellation into gyri, extreme values (defined as
±2.5 standard deviations from the group mean) were removed
from the analyses. Mean surface area and cortical thickness were
slightly but significantly different between recruitment centres
(t(16 564) = 5.15, P < 0.001 and t(16 494) = 6.43, P < 0.001 respect-
ively); therefore, ‘centre’ was added as a covariate in subsequent
analyses.
Analyses
Regression analyses including age, gender, intracranial volume and
centre as covariates were run to examine the association between cor-
tical measures and CNV carrier status. We first compared carriers of
any SCZ-associated CNV with non-carriers on overall brain and gyri
mean surface area and cortical thickness, to subsequently examine
the effect of each individual SCZ-associated CNV present in our
sample (only 6 SCZ-associated CNVs were present in >2 carriers
and were therefore analysed independently; Table 1).
To investigate structural covariance, z-transformed correlation
matrices were generated for thickness and surface area separately.
For each pair of gyri in the D–K atlas, the z-transformed correlation
across carriers was calculated. For a given gyrus, the average of the z-
Table 1 Association between specific copy number variant (CNV) carrier status and cortical surface area and thicknessa
CNV and number of carriers
Surface area, mm2 Thickness, mm
Total n β (P) Total n β (P)
1q21.1 del (n = 9) 16 456 −0.011 (0.006) 16 389 0.009 (0.198)
1q21.1 dup (n = 11) 16 459 −0.001 (0.858) 16 391 0.001 (0.933)
NRXN1 del (n = 6) 16 454 −0.007 (0.101) 16 386 −0.001 (0.850)
15q11.2 del (n = 59) 16 506 −0.016 (<0.001) 16 437 0.020 (0.006)
16p13.11 dup (n = 25) 16 473 −0.007 (0.088) 16 404 −0.003 (0.626)
16p12.1 del (n = 8) 16 456 −0.006 (0.148) 16 388 0.008 (0.261)
del, deletion; dup, duplication.
a. β-values were assigned to CNV carrier status after regressing out the effect of gender, age, intracranial volume and scanning centre. P-values that survived false discovery rate (FDR)
correction based on the 12 tests included in this table are highlighted in bold.
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transformed correlations with all other gyri provided a measure of
‘integration’ for that gyrus. An overall brain structural covariance
measure was calculated by averaging that metric across all gyri.
Additionally, two independent component analyses (ICAs) were
run for surface area and cortical thickness, setting the number of
components at 20. The mean structural covariance within each of
those components was calculated by weighting each gyrus’s covari-
ance by its relative weight in the ICA mixing matrix and taking the
average across all gyri. To compare these covariance metrics
between groups, null distributions were generated using a random
sampling procedure. A group of non-carriers the same size as the
carrier group was randomly selected and structural covariance
was calculated as above separately for surface area and cortical
thickness. This was repeated 100 000 times, generating a null distri-
bution for each pairwise gyrus comparison. An empirical P-value
could then be derived by counting the number of null samples in
which the absolute structural covariance value was greater than
the absolute value in the carriers.
Significance threshold was set at P < 0.05 (two-sided), and a
false discovery rate (FDR) of 0.10 (based on Benjamini–
Hochberg23) was used to correct for multiple testing. For the
overall brain’s surface area and cortical thickness, FDR correction
was applied on the basis of the 14 tests performed. For within-
gyri analyses, FDR correction was applied separately to each CNV
group comparison; i.e. FDR was based on the 136 tests that resulted
from comparing surface area and cortical thickness within each
gyrus across both hemispheres between carriers (or each individual
CNV) and non-carriers.
Results
Gender was evenly split (53% female) and equally distributed across
carriers and non-carriers (χ2(1) = 0.78, P > 0.1). The mean age was
55 years (s.d. = 7.46, range = 45–80), not differing between groups
(t(16 788) = 0.07, P > 0.1). Among carriers, 49% carried the most
common 15q11.2 deletion CNV; five of the rarer targeted CNVs
were not present in our sample (see supplementary Table 1).
Previous work from our group has shown consistency of individual
CNV frequencies between UK Biobank batches, and between the
UK Biobank and other independent control data-sets.14 As shown
in previous research,14,24 SCZ-associated CNV carrying status pre-
dicted performance IQ (fluid intelligence) (β =−0.04, P = 4 × 10−7)
and scores on the Townsend deprivation index (β = 0.02, P = 0.019)
in both cases, with carriers being disadvantaged.
Total brain surface area and cortical thickness
Carrying any SCZ-associated CNV was associated with surface area
reductions (β =−0.020 mm2, P < 0.001), but thicker cortex (β =
0.015 mm, P = 0.035). However, analyses on single CNVs showed
only the 1q21.1 deletion and the 15q11.2 deletion to be associated
with reduced surface area in carriers; and only the latter was also
associated with thicker cortex in carriers (Table 1).
Gyrus surface area and cortical thickness
Schizophrenia-associated CNV carrier status was associated with
surface area across several gyri bilaterally, although again associa-
tions appeared mainly driven by the 15q11.2 deletion. In all cases,
carriers showed reduced surface area (Fig. 1 and supplementary
Table 2a). Only one other SCZ-associated CNV, i.e. 1q21.1 duplica-
tion, showed FDR-corrected association with surface area. In this
case, though, it indicated reduced surface area in left isthmus cingu-
late in carriers, but increased surface area in right posterior cingu-
late. It is worth noting that left and right anterior cingulate along
with dorsal prefrontal areas also showed nominal larger surface area
in carriers of the 1q21.1 duplication (Fig. 1 and supplementary
Table 2(a)). In fact, this was the only SCZ-associated CNV that
showed positive associations with surface area, with all other SCZ-
associated CNVs showing only negative associations at either FDR-
corrected or nominal levels of significance (supplementary Table 2(a)).
The results for cortical thickness showed fewer significant asso-
ciations, mostly in right frontal cortex and left parietal regions.
Again, these results appeared mainly driven by the 15q11.2 deletion,
which showed more widespread significant effects when analysed
independently. The 1q21.1 deletion was also associated with thick-
ness in left postcentral gyrus, middle temporal gyrus and banks of
the superior temporal sulcus, and rostral middle frontal gyrus. In
all cases, carriers presented thicker cortices (Fig. 1 and supplemen-
tary Table 2(b)). No other FDR-corrected associations were found
(supplementary Tables 2(a) and 2(b)).
To examine the effect of overall brain size in the above results,
we repeated these analyses excluding intracranial volume as a covari-
ate. This only slightly changed the results for cortical thickness but had
a significant impact on results for surface area. The 15q11.2 deletion
lost its association with mean surface area (supplementary Table 3),
as well as seeing a reduction in effect size for most of the previously
significant associations with gyri’s surface area (supplementary
Table 4). The 1q21.1 deletion and duplication showed stronger asso-
ciations – negative and positive respectively – with mean surface area
and surface area across different gyri, this effect beingmore noticeable
in the deletion CNV that in this reanalysis showed significant associa-
tions with most brain gyri (supplementary Tables 3 and 4).
To exclude the possibility that our results are confounded by
population stratification, we repeated our main analyses including
the first ten principal components derived from common alleles
as covariates, obtaining the same results as before.
Structural covariance
Overall structural covariance for surface area was not different
between groups (carriers z = 0.16 versus non-carriers z = 0.14, P =
0.239), this being the case across all gyri (Fig. 2 and supplementary
Table 5(a)) and across the 20 ICA components (supplementary
Fig. 1). Structural covariance for cortical thickness, though, was glo-
bally increased in carriers compared with non-carriers (z = 0.31 v.
z = 0.22, P < 0.0005), this difference appearing widely spread across
gyri (Fig. 2 and supplementary Table 5(b)) and across 14 of the 20
ICA components (supplementary Fig. 1).
As regards individual SCZ-associated CNVs, the 15q11.2 dele-
tion and the 16p13.11 duplication were associated with increased
cortical thickness covariance mainly in frontal and parietal cortices
(Fig. 3 and supplementary Table 5(b)). No other CNV showed FDR-
corrected association with cortical thickness covariance, and none
of them did with surface area covariance. These results were repli-
cated comparing carrier groups on the structural covariance
across ICA components. Again the 15q11.2 deletion and 16p13.11
duplication showed increased thickness covariance across half the
components compared with non-carriers, and those mainly
included gyri within temporal and parietal lobules. The 1q21.1
duplication also showed a pattern of increased thickness covariance
relative to non-carriers similar to that for the aforementioned two
CNVs. No component showed group differences as regards
surface area covariance (supplementary Fig. 1).
Discussion
We report here significant associations between SCZ-associated
CNV carrier status and different indices of cortical anatomy.
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Surface area appeared reduced in SCZ-associated CNV carriers, fol-
lowing our prediction based on previous research in large clinical
samples – supporting this as a potential marker of risk for schizo-
phrenia. Cortical thickness, though, showed the opposite effect
than predicted; this is, thicker cortex in carriers. Structural covari-
ance for cortical thickness appeared to be increased in carriers, indi-
cating lack of flexibility or modularity across gyri. However, owing
to the novelty of our structural covariance approach this result
would require further replication. Finally, our results suggest large
heterogeneity of effects across individual SCZ-associated CNVs,
suggesting that different CNVs may be associated with different
mechanisms for schizophrenia.
We show that unaffected but high-genetic-risk participants (i.e.
carriers of SCZ-associated CNVs) present with smaller cortical
Surface area Cortical thickness
SCZ-associated CNV
15q11.2 deletion
1q21.1 deletion
1q21.1 duplication
Left hemisphere Left hemisphereRight hemisphere
β = –0.03 β = 0 β = 0.03
Right hemisphere
Fig. 1 Differences in cortical surface area (mm2) and thickness (mm) between carriers of schizophrenia-associated copy number variants (SCZ-
associated CNVs) and those not carrying CNVs, and carriers of individual SCZ-associated CNVs and those not carrying CNVs.
Gyri with nominal significant associations are coloured: warm colours for positive associations (carriers larger) and cold colours for negative associations (carriers smaller). Gyri in
which the association with CNV carrier status remained significant after false discovery rate (FDR) correction are marked with an asterisk (*). Only SCZ-associated CNVs that
presented with FDR-corrected significant associations are included in the figure (1q21.1duplication did not present any significant association with cortical thickness even before
FDR correction).
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surface area, coinciding with previous results shown in individuals
with schizophrenia.10,25 However, our carriers did show thicker
cortex, opposing previous results in clinical samples.10,25,26.
Interestingly, previous research on 22q11.2 deletions – a CNV
highly penetrant for schizophrenia but not observed in our
sample – also showed reductions in surface area, but rather wide-
spread thicker cortex in a mixed sample of unaffected and clinically
ascertained carriers.6 The authors of that research also showed that
carriers of the 22q11.2 deletion with psychosis had thinner frontal
and temporal cortices but did not differ in surface area from carriers
with no psychosis.6 Likewise, a recent paper looking into 15q11.2
deletions showed carriers to present smaller surface area but
thicker cortices, affecting mainly frontal regions.27 Thinning of
the cortex in schizophrenia has been associated with illness progres-
sion and severity, poor treatment outcome and use of antipsychotic
medication,10,28,29 whereas surface area has not shown association
with illness severity/progression indices,10 although admittedly
research on surface area is still scarce. Taking these together, cortical
thickness would appear to be associated with clinical state, rather
than with premorbid risk for schizophrenia, whereas surface area
behaves as would be expected from an indicator of risk for schizo-
phrenia, being present – albeit attenuated – in genetically at-risk but
unaffected participants. However, this interpretation should be cau-
tiously considered, since owing to their age, our SCZ-associated
CNV carriers are very unlikely to develop schizophrenia. Despite
both these brain measures being associated with performance IQ
(fluid intelligence) and the Townsend deprivation index score in
our sample, they did not appear to mediate the association
between SCZ-associated CNV carrying status and those phenotypic
measures (supplementary Table 6).
From our gyri and individual CNV analyses, it emerges that SCZ-
associated CNVs do not uniformly affect the brain, and that not all
SCZ-associated CNVs have similar effects on cortical anatomy.
Accepting the caveat that individual CNVs have different prevalence
rates in our sample and therefore some analyses would be more
powered than others, the 15q11.2 deletion appears to affect both
surface area and cortical thickness – concurring with previous
research27 – whereas no other SCZ-associated CNV appears to
affect both these brain markers. In fact, the only other two CNVs
showing FDR-corrected associations with cortical anatomy are
1q21.1 deletions and 1q21.1 duplications. These reciprocal CNVs
have been shown to be associated with head size – microcephaly in
deletion carriers and macrocephaly in duplication carriers30 – and
in fact they demonstrated changes in their association with surface
area, but not cortical thickness, when intracranial volume was not
included as covariate. Our results suggest that the association
between overall head size and these CNVs is mainly driven by their
effects on surface area. However, 1q21.1 deletion and duplication,
rather than showing a dose effect (affecting the samemetric in oppos-
ing directions), appear mainly to associate with different metrics:
1q21.1 deletions with thickness and 1q21.1 duplications with
surface area. Moreover, the 1q21.1 duplication is the only SCZ-asso-
ciated CNV in our sample to show positive associations with surface
area, all other SCZ-associated CNVs showing only negative associa-
tions even with uncorrected P < 0.05. The heterogeneity of effects
across CNVs was substantiated by the fact that comparing carriers
of SCZ-associated CNVs excluding 15q11.2 deletions (the most
prevalent CNV in our sample) with non-(CNV) carriers offered sub-
stantially different results than the comparison of carriers of 15q11.2
deletions with non-CNV carriers (supplementary Table 7 and Fig. 2),
and that the direct comparison between 15q11.2 deletion carriers
(n = 59) versus other SZ-CNV carriers (n = 61) resulted in significant
results despite the dramatic reduction in statistical power (supple-
mentary Table 7). We previously showed a rather homogeneous
effect across SCZ-associated CNVs on subcortical volumes,31
which appears not to be mirrored in the cortex. That result is
not surprising, though, in light of previous research showing
regional differences in genetic correlation for both cortical thick-
ness32 and surface area.33 Further replication in larger samples is
required, particularly for the less prevalent SCZ-associated CNVs.
This will also open the opportunity to investigate how individual
SCZ-associated CNVsmay associate with potential distinct down-
stream clinical characteristics, informing a neurobiologically
driven patient stratification.
Surface area
Cortical thickness
Left hemisphere Left hemisphere
–0.5 0.50
Right hemisphere
Non-carriers SZ-CNV Carriers Group difference
Right hemisphere Left hemisphere Right hemisphere
Fig. 2 Structural covariance index (averaged z-transformed correlation with all other gyri) for cortical surface area and thickness for carriers of
schizophrenia-associated copy number variants (CNVs) and non-carriers, and difference between groups.
In all cases the colour scheme at the bottom indicates the effect size (z-value for averaged maps, difference in z-value under ‘group difference’). Gyri with nominal significant
associations are coloured: warm colours for positive associations (carriers larger) and cold colours for negative associations (carriers smaller). Gyri in which the associationwith CNV
carrier status remained significant after false discovery rate (FDR) correction are marked with an asterisk (*).
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The structural covariance analyses showed higher brain integra-
tion with regard to cortical thickness than to surface area. Moreover,
the structural covariance topographical distribution across gyri was
almost identical in both cortical measures between SCZ-associated
CNV carriers and non-carriers, indicating no gross topological dif-
ferences. However, carriers showed higher thickness covariance
compared with non-carriers, this being mainly driven by the
15q11.2 deletion and the 16p13.11 duplication, mostly affecting
frontal and parietal cortices. The 1q21.1 duplication also showed
some association with increased thickness covariance, although in
this case that only survived correction for multiple testing when
reducing the number of comparisons via ICA. The pattern of asso-
ciations, though, was similar to the one shown by the 15q11.2 dele-
tion and the 16p13.11 duplication. Previous reports of increased
structural covariance in corticocortical networks in participants
with schizophrenia, alongside thinning of the cortex, have been
interpreted as an indication of neuronal over-pruning during ado-
lescence.12 This over-pruning explanation would not fit with our
findings of increased structural covariance in SCZ-associated
CNV carriers alongside thickening of the cortex. In keeping with
the interpretation of structural covariance as an index of develop-
mental trajectory integration,9 our results seem to suggest that
changes in thickness occurring in carriers would have more
widely affected the brain, whereas changes in surface area might
have affected the brain in a more modular manner, causing less
interdependency or covariance across gyri. Our study design,
however, does not allow us to investigate whether this higher covari-
ance indicates more integrated early thickness development related
to cell migration during prenatal development,29 deficient neuronal
pruning – in this case, lesser pruning – happening uniformly across
the brain during the first decades of life34 or a general slowing down
of the normal tissue loss in latter life if we take into account that our
participants were between 45 and 80 years of age.35
Limitations
Some caveats to this study should be noted. Despite including
∼17 000 participants, sample size remains a limitation. The advan-
tage of focusing on unaffected participants is obvious as regards
avoiding confounders associated with mental disorders (e.g. use of
medication). However, this strategy limits sample size because of
the high penetrance of SCZ-associated CNVs and therefore statis-
tical power. Future releases of UK Biobank’s imaging data – with
a final target of 100 000 participants – should allow a more
Surface area Cortical thickness
15q11.2 deletion
16q13.11 duplication
Left hemisphere Left hemisphereRight hemisphere
dz = –0.5 dz = 0.5dz = 0
Right hemisphere
Fig. 3 Differences in cortical surface area and thickness covariance between carriers of individual schizophrenia-associated copy number
variants (SCZ-associated CNVs) and those not carrying CNVs.
Gyri with nominal significant associations are coloured: warm colours for positive associations (carriers larger) and cold colours for negative associations (carriers smaller). Gyri
where the association with CNV carrier status remained significant after false discovery rate (FDR) correction are marked with an asterisk (*). Only SCZ-associated CNVs that
presented with FDR-corrected significant associations are included in the figure (16p13.11duplication did not present any significant association for surface area covariances even
before FDR correction).
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comprehensive investigation of the effects of these SCZ-associated
CNVs. Also, we obtained thickness and surface area measures on
the basis of the D–K atlas parcellation; however, genetic influences
over the brain may not necessarily follow the boundaries established
by gyri,32 causing a dilution of potential effects. Finally, owing to a
recruitment bias in the UK Biobank cohort, this is not a truly rep-
resentative sample of the general population,36 and it includes
fewer CNV carriers than would be expected on the basis of previous
prevalence data (for example, out of the initial 20 664 sample with
T1 data, there were no carriers of the 22q11.2 deletion, and even
before applying any of our inclusion criteria the sample included
only 7 more carriers of any SCZ-associated CNV). The sample
did not include any SCZ-associated CNV carriers positive to schizo-
phrenia, who would have been an interesting comparison group
against the unaffected SCZ-associated CNV carriers.
Implications for future research
Our results endorse that carrying rare risk alleles associated with
schizophrenia predicts reductions in cortical surface area in
unaffected participants, supporting the association of this metric
with genetic liability for the disorder in the absence of potential con-
founders associated with clinical state. Results for cortical thickness,
though, suggest that the thinning of the cortex previously reported
in patients is most likely to be a sequela of the disorder, or be unre-
lated to rare allele risk. Increased covariance for cortical thickness in
carriers also indicates larger integration of this measure across gyri,
suggesting less modularity in response to potential changes. We also
showed an important heterogeneity in the effects of individual SCZ-
associated CNVs over cortex, suggestive of distinct neurobiological
mechanisms in schizophrenia. Future research should investigate
whether risk associated with different SCZ-associated CNVs leads
to a shared singular symptom profile or to different symptom pro-
files under a common clinical diagnostic – but phenotypically het-
erogeneous – label.
Xavier Caseras , PhD, MRC Centre for Neuropsychiatric Genetics and Genomics,
Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, UK;
George Kirov , MD, PhD, MRC Centre for Neuropsychiatric Genetics and Genomics,
Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, UK;
Kimberley M. Kendall, MBBCh, MRC Centre for Neuropsychiatric Genetics and
Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff
University, UK; Elliott Rees, PhD, MRC Centre for Neuropsychiatric Genetics and
Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff
University, UK; Sophie E. Legge , PhD, MRC Centre for Neuropsychiatric Genetics and
Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff
University, UK; Matthew Bracher-Smith, BSc, MRC Centre for Neuropsychiatric
Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences,
Cardiff University, UK; Valentina Escott-Price, PhD, MRC Centre for Neuropsychiatric
Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences,
Cardiff University; and UK Dementia Research Institute, Cardiff University, UK;;
Kevin Murphy, PhD, Cardiff University Brain Research Imaging Centre (CUBRIC), School
of Physics and Astronomy, Cardiff University, UK
Correspondence: Dr Xavier Caseras. Email: caserasx@cardiff.ac.uk
First received 21 Feb 2020, final revision 18 Jun 2020, accepted 20 Jun 2020
Supplementary material
Supplementary material is available online at http://doi.org/10.1192/bjp.2020.139.
Data availability
All data used in this research are publicly available to researchers on application to UK Biobank:
www.ukbiobank.ac.uk.
Acknowledgements
We thank the UK Biobank for access to its data (under project 17044).
Author contributions
Conceptualisation: X.C., G.K., K.M.; methodology: X.C., E.R., K.M.; imaging data preparation,
X.C., K.M.; phenotypic data preparation: X.C., K.M.K., M.B.-S.; genetic data preparation:
K.M.K., E.R., S.E.L.; analyses: X.C., K.M., VEC; original draft: X.C., E.R., K.M.; revision: X.C.,
G.K., K.M.K., E.R., S.E.L., M.B.-S., V.E.-P., K.M.
Funding
This research was supported by the Medical Research Council Programme grant (G08005009).
K.M. is supported by a Wellcome Senior Research Fellowship (WT200804).
Declaration of interest
None.
ICMJE forms are in the supplementary material, available online at http://doi.org/10.1192/
bjp.2020.139.
References
1 Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence
from a meta-analysis of twin studies. Arch Gen Psychiatry 2003; 60: 1187–92.
2 Pardiñas A, Holmans P, Pocklington A, Escott-Price V, Ripke S, Carrera N, et al.
Common schizophrenia alleles are enriched in mutation-intolerant genes and
in regions under strong background selection. Nat Genet 2018; 50: 381–9.
3 Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS,
et al. Contribution of copy number variants to schizophrenia from a genome-
wide study of 41,321 subjects. Nat Genet 2017; 49: 27–35.
4 Stefansson H, Meyer-Lindenberg A, Steinberg S, Magnusdottir B, Morgen K,
Amarsdottir S, et al. CNVs conferring risk of autism or schizophrenia affect
cognition in controls. Nature 2014; 505: 361–6.
5 Qureshi AY, Mueller S, Snyder AZ, Mukherjee P, Berman JI, Roberts TP, et al.
Opposing brain differences in 16p11.2 deletion and duplication carriers.
J Neurosci 2014; 34: 11199–211.
6 SunD, Ching CRK, Lin A, Forsyth JK, Kishan L, Vajdi A, et al. Large-scalemapping
of cortical alterations in 22q11.2 deletion syndrome: convergence with idio-
pathic psychosis and effects of deletion size. Mol Psychiatry [Epub ahead of
print] 13 Jun 2018. Available from: https://doi.org/10.1038/s41380-018-0078-5.
7 Winker AM, Kochunov P, Blangero J, Almasy L, Zilles K, Fox PT, et al. Cortical
thickness of grey matter volume? The importance of selecting the phenotype
for imaging genetics. Neuroimage 2010; 53: 1135–46.
8 Schmitt JE, Lenroot RK, Wallace GL, Ordaz S, Taylor KN, Kabani N, et al.
Identification of genetically mediated cortical networks: amultivariate study of
pediatric twins and siblings. Cereb Cortex 2008; 18: 1737–47.
9 Alexander-Bloch A, Raznahan A, Bullmore E, Giedd J. The convergence of
maturational changes and structural covariance in human cortical networks.
J Neurosci 2013; 33: 2889–99.
10 van Erp TGM, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, et al. Cortical
brain abnormalities in 4474 individuals with schizophrenia and 5098 control
subjects via the Enhancing Neuro Imaging Genetics through Meta Analysis
(ENIGMA) consortium. Biol Psychiatry 2018; 84: 644–54.
11 Zalesky A, Pantelis C, Cropley V, Fornito A, Cocchi L, McAdamsH, et al. Delayed
development of brain connectivity in adolescents with schizophrenia and their
unaffected siblings. JAMA Psychiatry 2015; 72: 900–8.
12 Alexander-Bloch A, Giedd JN, Bullmore E. Imaging structural co-variance
between human brain regions. Nat Rev Neurosci 2013; 14: 322–36.
13 Legge SE, Jones HJ, Kendall KM, Pardiñas AF, Menzies G, Bracher-Smith M,
et al. Association of genetic liability to psychotic experiences with neuropsy-
chotic disorder and traits. JAMA Psychiatry 2019; 76: 1256–65.
14 Kendall KM, Rees E, Escott-Price V, EinonM, Thomas R, Hewitt J, et al. Cognitive
performance among carriers of pathogenic copy number variants: analysis of
152,000 UK Biobank subjects. Biol Psychiatry 2017; 82: 103–10.
15 Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, et al. PennCNV: an inte-
grated hidden Markov model designed for high-resolution copy number vari-
ation detection in whole-genome SNP genotyping data. Genome Res 2007; 17:
1665–74.
16 Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J, et al. Copy number
variants in schizophrenia: confirmation of five previous findings and new evi-
dence for 3q29 microdeletions and VIPR2 duplications. Am J Psychiatry 2011;
168: 302–16.
17 Rees E, Walters JT, Georgieva L, Isles AR, Chambert KD, Richards AL, et al.
Analysis of copy number variations at 15 schizophrenia-associated loci. Br J
Psychiatry 2014; 204: 108–14.
Schizophrenia‐associated CNVs and cortical anatomy
7
Downloaded from https://www.cambridge.org/core. 23 Nov 2020 at 13:54:06, subject to the Cambridge Core terms of use.
18 Rees E, Kendall K, Pardiñas AF, Legge SE, Pocklington A, Escott-Price V, et al.
Analysis of intellectual disability copy number variants for association with
schizophrenia. JAMA Psychiatry 2016; 73: 963–9.
19 Dittwald P, Gambin T, Szafranski P, Li J, Amato S, Divon MY, et al. NAHR-
mediated copy-number variants in a clinical population: mechanistic insights
into both genomic disorders and Mendelizing traits. Genome Res 2013; 23:
1395–409.
20 Coe BP, Witherspoon K, Rosenfeld JA, van Bon BW, Vulto-van Silfhout AT,
Bosco P, et al. Refining analyses of copy number variation identifies spe-
cific genes associated with developmental delay. Nat Genet 2014; 46:
1063–71.
21 Alfaro-Almagro F, Jenkinson M, Bangerter NK, Andersson JLR, Griffanti L,
Douaud G, et al. Image processing and Quality Control for the first 10,000 brain
imaging datasets from UK Biobank. Neuroimage 2018; 166: 400–24.
22 Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al.
An automated labeling system for subdividing the human cerebral cortex
on MRI scans into gyral based regions of interest. Neuroimage 2006; 31:
968–80.
23 Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: a practical and
powerful approach to multiple testing. J R Statist Soc B 1995; 57: 289–300.
24 Kendall KM, Bracher-Smith M, Fitzpatrick H, Lynham A, Rees E, Escott-Price V,
et al. Cognitive performance and functional outcomes of carriers of pathogenic
copy number variants: analysis of the UK Biobank. Br J Psychiatry 2019; 214:
297–304.
25 Rimol LM, Nesvåg R, Hagler DJ, Bergmann Ø, Fennema-Notestine C, Hartberg
CB, et al. Cortical volume, surface area, and thickness in schizophrenia and
bipolar disorder. Biol Psychiatry 2012; 71: 552–60.
26 Goldman AL, Pezawas L, Mattay VS, Fischl B, Verchinski BA, Chen Q, et al.
Widespread reductions of cortical thickness in schizophrenia and spectrum
disorders and evidence of heritability. Arch Gen Psychiatry 2009; 66:
467–77.
27 Writing Committee for the ENIGMA-CNV Working Group. Association of copy
number variation of the 15q11.2 BP1-BP2 region with cortical and subcortical
morphology and cognition. Mol Psychiatry 2020; 77: 420–30.
28 van Haren NEM, Schnack HG, Cahn W, van den Heuvel MP, Lepage C, Collin L,
et al. Changes in cortical thickness during the course of illness in schizophre-
nia. Arch Gen Psychiatry 2011; 68(9): 871–80.
29 Ahmed M, Cannon DM, Scanlon C, Holleran L, Schmidt H, McFarland J, et al.
Progressive brain atrophy and cortical thinning in schizophrenia after
commencing clozapine treatment. Neuropsychopharmacology 2015; 40:
2409–17.
30 Brunetti-Pierri N, Berg JS, Scaglia F, Belmont J, Bacino CA, Sahoo T, et al.
Recurrent reciprocal 1q21.1 deletions and duplications associated with
microcephaly or macrocephaly and developmental and behavioral abnormal-
ities. Nat Genet 2008; 40: 1466–71.
31 Warland A, Kendall KM, Rees E, Kirov G, Caseras X. Schizophrenia-associated
genomic copy number variations and subcortical brain volumes in the UK
Biobank. Mol Psychiatry 2020; 25: 854–62.
32 Rimol LM, Panizzon MS, Fennema-Notestine C, Eyler LT, Fischl B, Franz CE,
et al. Cortical thickness is influenced by regionally specific genetic factors. Biol
Psychiatry 2010; 67: 493–9.
33 Chen C, Gutierrez ED, Thompson W, Panizzon MS, Jerningan TL, Eyler LT, et al.
Hierarchical genetic organization of human cortical surface area. Science
2012; 335: 1634–6.
34 Shaw P, Kabani NJ, Lerch JP, Eckstrand K, Lenroot R, Gogtay N, et al.
Neurodevelopmental trajectories of the human cerebral cortex. J Neurosci
2008; 28: 3586–94.
35 Jernigan TL, Archibald SL, Fennema-Notestine C, Gamst AC, Stout JC, Bonner J,
et al. Effects of age on tissue and regions of the cerebrum and cerebellum.
Neurobiol Aging 2001; 22: 581–94.
36 Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al.
Comparison of sociodemographic and healthy-related characteristics of UK
Bionbank participants with those of the general population. Am J Epidemiol
2017; 186: 1026–34.
Caseras et al
8
Downloaded from https://www.cambridge.org/core. 23 Nov 2020 at 13:54:06, subject to the Cambridge Core terms of use.
